Statistics from Altmetric.com
Over the past two decades, treatment of juvenile idiopathic arthritis (JIA) has improved immensely, and much of this improvement pre-dates the use of new biologic drugs. This is largely due to greater willingness to use methotrexate, a long-established disease-modifying agent, early in the disease, and greater use of intra-articular corticosteroid injections: getting the steroid directly into the joint is effective and avoids most of the side-effects.
What hasn’t been clear is whether these two modalities should be used together early on in the majority of children who present with relatively mild, …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.